by Elena Iemma | Feb 23, 2024 | Blog
ISPRI for Bi-Specifics? Yes, we Can! In With the New! At this point in our evolution as a company, we can affirm that change is good! As promised, EpiVax 2.0 is emerging in 2024, with new products and new leaders! First, say hello to our...
by Elena Iemma | Dec 23, 2023 | Blog
FDA Request for “Integrated Summary of Immunogenicity” So much news to share! EpiVax Delivers! As promised, EpiVax 2.0 will be arriving in 2024, our 26th year, along with new team members and new plans to expand the range of services offered. Here...
by Elena Iemma | May 17, 2023 | News
PROVIDENCE, RI, May 17, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition,...
by Elena Iemma | May 16, 2023 | News
EpiVax is celebrating 25 years of innovative immunoinformatics tool development. The company’s mission is to improve the safety and efficacy of vaccines and protein therapeutics, while working to improve human health everywhere. 1998 EpiVax...
by Elena Iemma | Sep 12, 2022 | News
PROVIDENCE, RI, September 12, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk...
